VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results f... (007. The largest research and developmen...)

VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008

Date:8/29/2008

007. The largest research and development expense for the three months ended June 30, 2008 was payroll costs to build a highly qualified research and development team.

VentriPoint reported a foreign exchange loss of $99,568 as the result of a change in the currency exchange rate used to translate Canadian monetary items into the US dollar on the date of translation of June 30, 2008.

About VentriPoint Diagnostics

VentriPoint creates diagnostic tools to monitor patients with heart disease -- the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Diagnostic System generates accurate heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon patented technology received by VentriPoint through its exclusive technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.

For further information, please contact:

Edward Garth, Chief Financial Officer

VentriPoint Diagnostics Ltd.

Telephone: (206) 283-0221, ext. 402

Facsimile: (206) 283-2309

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

VentriPoint Media Contact:

Russo Partners LLC

Ian Stone

(619) 814-3510

ian.stone@russopartnersllc.com

SOURCE VentriPoint Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. VentriPoint, University of Washington Sign Research and Technology Development Agreement
2. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
3. Strategic Diagnostics Updates Roth Conference Presentation Time
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
8. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
9. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
10. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
11. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)

Post Your Comments:

(Date:12/15/2009)... 15 Reportlinker.com announces that a ... its catalogue: ,, The Future ... to 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The ... Future of Orphan Diseases Therapeutics - Market ...

(Date:12/15/2009)... Dec. 15 AstraZeneca (NYSE: ... Virginia (UVa) in Charlottesville, today announced that ... collaboration to enhance development of new treatments ... a secondary focus on peripheral vascular disease ... ,, The collaborative preclinical research projects will ...

(Date:12/15/2009)... PLYMOUTH, Minn., Dec. 15 The Mosaic Company (NYSE: ... quarter fiscal year 2010 earnings results and financial tables ... trading on the New York Stock Exchange. Results ... ,, The Company will host a conference call ... discuss the results. The call will begin at ...

(Date:12/15/2009)... -- The Center for Business Intelligence (CBI), ... to announce the full agenda for the ... Congress . The forum will take place ... 2010. ,, Over 1,500 senior-level Finance, Accounting, ... premier event since its inception, and this ...

[0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease [0] Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call [0] CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress

... 21 LeMaitre Vascular,Inc. (Nasdaq: LMAT ), ... acquired Biomateriali S.r.l., a privately held Italian,vascular graft ... assumption,of euro 0.8 million in intercompany liabilities, and ... The acquisition was structured as a stock,purchase., ...

... be Only Once-Yearly Implant for Prostate Cancer in ... Indevus Reaffirms Commitment to Prostate Cancer Patients, ... (Nasdaq: IDEV ) today commented on the ... their product,Viadur(R) (leuprolide acetate implant), which is indicated ...

... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... double-blind, placebo-controlled Phase 2a clinical,trial of MEM 3454, ... cognitive impairment associated with schizophrenia (CIAS). The,trial is ... effects,of three doses of MEM 3454 in patients ...

Other Biology Technology:LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 2 LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 3 Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R) 2 Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R) 3 Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 2 Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 3 Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 4

LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

(Date:12/16/2009)... N.J., Dec. 9 BIO-key International, ... in finger-based biometric identification solutions, today announced ... most respected security publications, named BIO-key International ... the Access Control sub-category Biometrics. ,, (Logo: ... Peter Stephenson, technology editor, SC Magazine, "Biometric ...

(Date:12/16/2009)... 16 European Union (EU) member ... borders, which are increasingly subjected to unauthorised ... in advanced technology security and IT-based systems ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, New analysis ... Border Security Market Assessment - European ...

(Date:12/15/2009)... As soon as babies are born, they are susceptible ... For up to a month, their immune systems aren,t ... often minor, they can lead to serious problems if ... of Missouri researchers have pinpointed a group of depleted ... vaccine. , "We,re trying to improve the immune system ...

Breaking Biology News(10 mins):BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2 BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3 Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2 Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3 Researchers work on vaccine to improve immune system in newborns 2 Researchers identify new brain pathway for regulating weight and bone mass 10065 1 Researchers identify new brain pathway for regulating weight and bone mass 10065 2 Cambridge Healthtech Institute and Bio IT World Launch a New eNewsletter 3A Pharma Services News 58168 1 Cambridge Healthtech Institute and Bio IT World Launch a New eNewsletter 3A Pharma Services News 58168 2 5th Annual Stem Cell Summit Set for Feb 16 in New York City 58163 1 5th Annual Stem Cell Summit Set for Feb 16 in New York City 58163 2 5th Annual Stem Cell Summit Set for Feb 16 in New York City 58163 3

[0] BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine [0] Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan [0] Researchers work on vaccine to improve immune system in newborns

... a type of blue-green algae known as Nostoc, shows promise ... other neurodegenerative diseases, according to an in vitro study by ... time that a potent agent against Alzheimer's has been isolated ... published in the Dec. 26 issue of the Journal ...

... been used to track the source of illegal drugs, ... some new uses: detecting rapidly growing cancers and studying ... "stable isotope ratio mass spectrometry," can determine where a ... of an element in the substance ?such as the ...

... Institute for Biomedical Research have successfully demonstrated that ... is indeed possible, at least in mice. ... (ANT), proposes that researchers first create genetically altered ... uterus, and then extract stem cells from these ...

Other Biology News:Natural compound from 'pond scum' shows potential activity against Alzheimer's 2 War on terror meets war on cancer 2 War on terror meets war on cancer 3 War on terror meets war on cancer 4 War on terror meets war on cancer 5 War on terror meets war on cancer 6 Researchers offer proof-of-concept for Altered Nuclear Transfer 2 Researchers offer proof-of-concept for Altered Nuclear Transfer 3

Natural compound from 'pond scum' shows potential activity against Alzheimer's War on terror meets war on cancer Researchers offer proof-of-concept for Altered Nuclear Transfer

One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....

[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...

...

One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....

Biology Products:

Hemoglobin Colorimetric Assay Kit, QuantiChrom from BioAssay Systems Prostaglandin D2 , 5,6,8,9,12,14,15(n)-3H Conjugated/Tagged from GE Healthcare, formerly Amersham Biosciences 10% Normal Rabbit Serum from Invitrogen QuantiChrom™ Sulfate Assay Kit from BioAssay Systems

VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results f...(007. The largest research and developmen...)